Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

HER3-DXd demonstrates similar efficacy compared to multi-agent chemotherapy in high-risk HR-positive/HER2-negative eBC

Dr Mafalda Oliveira - Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
HER3-DXd demonstrates similar efficacy compared to multi-agent chemotherapy in high-risk HR-positive/HER2-negative eBC ( Dr Mafalda Oliveira - Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )
19 Dec 2024

Post-chemo olaparib continues to improve efficacy in gBRCApv and high-risk, HER2-negative primary breast cancer

Dr Judy Garber - Dana-Farber Cancer Institute, Boston, USA
Post-chemo olaparib continues to improve efficacy in gBRCApv and high-risk, HER2-negative primary breast cancer ( Dr Judy Garber - Dana-Farber Cancer Institute, Boston, USA )
18 Dec 2024

Immediate breast surgery versus deferral of surgery in women aged 70+ years with operable breast cancer

Prof Robert Hills - University of Oxford, Oxford, United Kingdom
Immediate breast surgery versus deferral of surgery in women aged 70+ years with operable breast cancer ( Prof Robert Hills - University of Oxford, Oxford, United Kingdom )
18 Dec 2024

Teclistamab-lenalidomide and teclistamab alone can be safely administered as maintenance therapy following ASCT in NDMM

Dr Elena Zamagni - University of Bologna, Bologna, Italy
Teclistamab-lenalidomide and teclistamab alone can be safely administered as maintenance therapy following ASCT in NDMM ( Dr Elena Zamagni - University of Bologna, Bologna, Italy )
18 Dec 2024

Mosunetuzumab SC plus polatuzumab vedotin demonstrates improved outcomes versus rituximab plus polatuzumab vedotin in RR LBCL

Dr Adam Olszewski - Brown University, Providence, USA
Mosunetuzumab SC plus polatuzumab vedotin demonstrates improved outcomes versus rituximab plus polatuzumab vedotin in RR LBCL ( Dr Adam Olszewski - Brown University, Providence, USA )
18 Dec 2024

Acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy for first-line treatment of CLL

Dr Jennifer Brown - Dana-Farber Cancer Institute, Boston, USA
Acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy for first-line treatment of CLL ( Dr Jennifer Brown - Dana-Farber Cancer Institute, Boston, USA )
18 Dec 2024

Primary IVIG supplementation reduces the risk of high-grade infections in patients receiving teclistamab therapy for MM

Dr Heloise Cheruvalath - Medical College of Wisconsin, Milwaukee, USA
Primary IVIG supplementation reduces the risk of high-grade infections in patients receiving teclistamab therapy for MM ( Dr Heloise Cheruvalath - Medical College of Wisconsin, Milwaukee, USA )
18 Dec 2024

Glofitamab with rituximab, ifosfamide, carboplatin and etoposide shows favourable efficacy in RR diffuse large B-cell lymphoma

Dr Paolo Caimi - Cleveland Clinic, Cleveland, USA
Glofitamab with rituximab, ifosfamide, carboplatin  and etoposide shows favourable efficacy in RR diffuse large B-cell lymphoma ( Dr Paolo Caimi - Cleveland Clinic, Cleveland, USA )
18 Dec 2024

Nivolumab and ipilimumab shows a significantly higher OS rate in nccRCC compared to standard of care

Prof Jens Bedke - Klinikum Stuttgart-Katharinenhospital, Stuttgart, Germany
Nivolumab and ipilimumab shows a significantly higher OS rate in nccRCC compared to standard of care ( Prof Jens Bedke - Klinikum Stuttgart-Katharinenhospital, Stuttgart, Germany )
17 Dec 2024

Analysis of dexamethasone-enhanced pre-medication in motixafortide-induced haematopoietic stem cell mobilisation for MM

Dr Peter Abdelmessieh - Fox Chase Cancer Center, Philadelphia, USA
Analysis of dexamethasone-enhanced pre-medication in motixafortide-induced haematopoietic stem cell mobilisation for MM ( Dr Peter Abdelmessieh - Fox Chase Cancer Center, Philadelphia, USA )
17 Dec 2024

Pembrolizumab after chemo demonstrates promising activity in low-risk cHL

Prof Christine Mauz-Koerholz - Justus Liebig University, Giessen, Germany
Pembrolizumab after chemo demonstrates promising activity in low-risk cHL ( Prof Christine Mauz-Koerholz - Justus Liebig University, Giessen, Germany )
17 Dec 2024

Analysis of pre-treatment biomarkers associated with toxicity and durable responses in idecabtagene vicleucel therapy for RRMM

Dr Doris Hansen - Moffitt Cancer Center, Tampa, USA
Analysis of pre-treatment biomarkers associated with toxicity and durable responses in idecabtagene vicleucel therapy for RRMM ( Dr Doris Hansen - Moffitt Cancer Center, Tampa, USA )
17 Dec 2024